AGILE THERAPEUTICS INC: Nasdaq/NYSE listing notice — Agile Therapeutics receives Nasdaq deficiency notice for negative stockholders' equity

AGILE THERAPEUTICS INC

Stockholders' equity of -$5.545M as of Dec 31, 2022, below Nasdaq's $2.5M minimum requirement.
Company has until May 11, 2023 to submit a compliance plan to regain listing compliance.
No immediate effect on Nasdaq listing; company intends to submit a plan and consider options.
Alternative compliance standards (market value or net income) also not met.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

AGILE THERAPEUTICS INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

(the “Stockholders’ Equity Requirement”). The Company’s Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2022, reported stockholders’ equity of $(5,545,000), which is below the Stockholders’ Equity Requirement for continued listing on the Nasdaq Capital Market. As of the date of this Current Report on Form 8-K, the Company does not

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001558370-23-005100

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.